CPT code 80299 is an unlisted laboratory code for therapeutic drug quantitation procedures that lack a specific CPT descriptor. Nationally, unlisted codes like 80299 matter because they capture nonstandard or emerging assays used to monitor drug levels for therapeutic management, impacting billing clarity, prior authorization, and reimbursement pathways. The code is relevant to clinical laboratories, hospital labs, and clinicians managing drug therapies that require precise quantitation when no specific CPT code exists.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how 80299 is used in clinical practice, typical sites of service, and common considerations for reporting an unlisted therapeutic drug quantitation test. The publication also outlines expected benchmarking topics and policy issues readers can expect: claim submission guidance for unlisted laboratory procedures, payer adjudication patterns, documentation needs to support medical necessity, and implications for lab operations and clinician communication.

This summary provides concise context for stakeholders seeking clarity on when to report 80299, what national payers typically consider when reviewing unlisted therapeutic drug quantitation claims, and the types of policy and clinical topics covered in the full publication. Data not available in the input.